Tag:
BARDA
Latest Headlines
Latest Headlines
Biota plots U.S. move in Nabi Bio merger
Today, Nabi's new strategy took shape in the form of a merger with Australia's flu drug developer Biota, which is now moving its headquarters to the U.S.
Cleveland BioLabs shares tank after BARDA drops support
Shares of Cleveland BioLabs ($CBLI) were trounced yesterday as word spread that a division of Health and Human Services had turned a cold shoulder to its experimental treatment for radiation poisoning.
Cellerant grabs $16.7M for radiation sickness therapy
Cellerant Therapeutics is getting another big boost from Uncle Sam. The Biomedical Advanced Research and Development Authority (BARDA) has provided the San Carlos, CA-based developer another $16.7
BARDA continues support of pre- and post-exposure Anthrax vax
Intramuscular injection of an anthrax prophylactic has sustained the attention of the U.S. Biomedical Advanced Research & Development Authority (BARDA) to the tune of $68 million. New
BARDA backs GSK antibiotic with $94M in R&D support
The U.S. government's bioterror drug development arm, BARDA, has stepped up with a $94 million contract to support the development of a new gram-negative antibiotic in GlaxoSmithKline's ($GSK)
U.S. gives out $5M for anti-radiation drugs in case of attack
The Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services, has awarded a total of about $5 million in research grants to two companies
BARDA grants Australia's Biota $231M flu vaccine contract
Just a month after granting major contracts to VaxInnate and Novavax , BARDA is giving $231 million to Australia-based Biota for the company's flu treatment laninamivir. The drug is a long acting
WSJ: Siga's billionaire owner could derail $2.8B drug contract
Just weeks after Siga Technologies ( $SIGA ) announced that it has been tapped as the likely winner of a $2.8 billion federal contract for a new smallpox drug, the SBA is now threatening to blow up the
Cellerant lands $153M BARDA contract for ARS program
San Carlos, CA-based Cellerant Therapeutics--a 2005 Fierce 15 company--is getting a big boost from the Biomedical Advanced Research and Development Authority, which has inked a $153 million contract
